Ainos (AIMD)
NASDAQ:AIMD
Want to see AIMD full AI Analyst Report?
Top Page
Ainos
(NASDAQ:AIMD)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▼(-12.28% Downside)
Action:ReiteratedDate:04/19/26
The score is held down primarily by weak financial performance—recurring losses, ongoing cash burn, and rising leverage—despite improved 2025 gross margin. Technicals provide some support from a short-term uptrend, but overbought signals and a weak longer-term trend temper that. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Proprietary AI Nose platform
The company’s AI Nose platform represents a durable, platform-based business model: a core sensing technology applicable to diagnostics and drug development. Platform scalability and multiple use cases (point-of-care, monitoring, drug programs) support structural growth if adoption and regulatory paths progress.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow (~-$4.6M in 2025) is a structural weakness: it necessitates frequent external funding, risks dilution, and constrains investment. Until the company achieves consistent positive operating cash flow, financing dependencies will limit long-term financial flexibility and strategy execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary AI Nose platform
The company’s AI Nose platform represents a durable, platform-based business model: a core sensing technology applicable to diagnostics and drug development. Platform scalability and multiple use cases (point-of-care, monitoring, drug programs) support structural growth if adoption and regulatory paths progress.
Read all positive factors
Ainos (AIMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.50M
Dividend YieldN/A
Average Volume (3M)78.00K
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue Growth498.95%
EPS Growth58.40%
CountryUS
Employees44
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding7,266,011
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue144.55
Enterprise Value/Gross Profit174.39
Enterprise Value/Ebitda-1.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ainos Business Overview & Revenue Model
Company Description
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based tes...
How the Company Makes Money
null...
Ainos Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 124.16K | 20.73K | 122.11K | 3.52M | 594.56K |
| Gross Profit | 102.91K | -31.87K | -253.73K | 1.41M | 410.38K |
| EBITDA | -9.28M | -9.44M | -8.77M | -9.14M | -1.83M |
| Net Income | -14.77M | -14.86M | -13.77M | -14.01M | -3.89M |
Balance Sheet | |||||
| Total Assets | 20.87M | 28.82M | 31.84M | 37.11M | 40.82M |
| Cash, Cash Equivalents and Short-Term Investments | 417.35K | 3.89M | 1.89M | 1.85M | 1.75M |
| Total Debt | 11.00M | 12.00M | 5.96M | 1.27M | 3.62M |
| Total Liabilities | 13.31M | 13.30M | 7.39M | 2.48M | 30.63M |
| Stockholders Equity | 7.56M | 15.52M | 24.45M | 34.63M | 10.20M |
Cash Flow | |||||
| Free Cash Flow | -4.65M | -5.83M | -4.79M | -3.67M | -1.39M |
| Operating Cash Flow | -4.61M | -5.81M | -4.69M | -3.04M | -1.25M |
| Investing Cash Flow | -2.22K | -125.29K | -101.53K | -630.18K | -180.52K |
| Financing Cash Flow | 1.01M | 8.03M | 4.92M | 3.85M | 3.15M |
Ainos Technical Analysis
Positive
2.28
Price Trends
1.55
Positive
1.78
Positive
2.53
Negative
Market Momentum
0.06
Negative
71.89
Negative
67.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Positive. The current price of 2.2800000000000002 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.55, and below the 200-day MA of 2.53, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 71.89 is Negative, neither overbought nor oversold. The STOCH value of 67.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIMD.
Ainos Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
51 Neutral | $11.42M | -9.61 | -22.03% | ― | -95.92% | 96.05% | |
48 Neutral | $12.50M | -0.39 | -119.35% | ― | 498.95% | 58.40% | |
43 Neutral | $10.50M | -1.16 | -89.92% | ― | ― | 58.63% | |
42 Neutral | $4.60M | -0.54 | -1292.87% | ― | ― | -30.18% | |
40 Underperform | $3.48M | -0.63 | -248.01% | ― | ― | 55.44% |
* Technology Sector Average
AIMD
Ainos
1.72
-0.93
-35.09%
BLRX
Bioline RX Ltd Sponsored ADR
3.07
-0.40
-11.53%
SNGX
Soligenix
0.34
-1.63
-82.84%
CMMB
Chemomab Therapeutics
1.46
-3.94
-72.96%
FBLG
FibroBiologics, Inc.
1.31
-21.09
-94.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.